• VRD versus VCD as induction therapy before autologous stem cell transplantation in multiple myeloma: a nationwide population-based study 

      Nørgaard, Jakob Nordberg; Moore, Kari Lenita Falck; Slørdahl, Tobias Schmidt; Vik, Anders; Tvedt, Tor Henrik Anderson; Schjesvold, Fredrik (Journal article; Tidsskriftartikkel; Peer reviewed, 2024-04-09)
      Induction therapy followed by autologous stem cell transplantation (ASCT) is standard of care for young and fit patients with newly diagnosed multiple myeloma (MM) [1]. Induction therapy has evolved from doublet to triplet to quadruplet regimens over the last decades. The most common triplet therapy is either Bortezomib-Cyclophosphamide-Dexamethasone (VCD), Bortezomib-Lenalidomide-Dexamethasone ...